WO2000063415A8 - Dna encoding the human vanilloid receptor vr1 - Google Patents

Dna encoding the human vanilloid receptor vr1

Info

Publication number
WO2000063415A8
WO2000063415A8 PCT/US2000/009897 US0009897W WO0063415A8 WO 2000063415 A8 WO2000063415 A8 WO 2000063415A8 US 0009897 W US0009897 W US 0009897W WO 0063415 A8 WO0063415 A8 WO 0063415A8
Authority
WO
WIPO (PCT)
Prior art keywords
dna encoding
receptor
host cells
vanilloid receptor
recombinant
Prior art date
Application number
PCT/US2000/009897
Other languages
French (fr)
Other versions
WO2000063415A1 (en
Inventor
Adrienne Dubin
Mark Erlander
Kathryn E Rogers
Arne Huvar
Rene Huvar
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Priority to CA002370570A priority Critical patent/CA2370570A1/en
Priority to JP2000612492A priority patent/JP2003520022A/en
Priority to EP00922143A priority patent/EP1175504A4/en
Priority to AU42374/00A priority patent/AU4237400A/en
Publication of WO2000063415A1 publication Critical patent/WO2000063415A1/en
Publication of WO2000063415A8 publication Critical patent/WO2000063415A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

DNA encoding human VR1 receptor has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
PCT/US2000/009897 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1 WO2000063415A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002370570A CA2370570A1 (en) 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1
JP2000612492A JP2003520022A (en) 1999-04-15 2000-04-13 DNA encoding human vanilloid receptor VR1
EP00922143A EP1175504A4 (en) 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1
AU42374/00A AU4237400A (en) 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29270099A 1999-04-15 1999-04-15
US09/292,700 1999-04-15

Publications (2)

Publication Number Publication Date
WO2000063415A1 WO2000063415A1 (en) 2000-10-26
WO2000063415A8 true WO2000063415A8 (en) 2001-01-18

Family

ID=23125812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009897 WO2000063415A1 (en) 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1

Country Status (5)

Country Link
EP (1) EP1175504A4 (en)
JP (1) JP2003520022A (en)
AU (1) AU4237400A (en)
CA (1) CA2370570A1 (en)
WO (1) WO2000063415A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4444493B2 (en) 1997-08-20 2010-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Nucleic acid sequences encoding capsaicin receptors and capsaicin receptor related polypeptides and uses thereof
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6482611B1 (en) 1999-09-23 2002-11-19 Neurogen Corporation Human capsaicin receptor and uses thereof
EP1170365A1 (en) * 2000-07-04 2002-01-09 Smithkline Beecham Plc Member of the ion channel family of polypeptides; vanilrep4
EP1313768B1 (en) 2000-09-02 2008-02-06 Grünenthal GmbH Antisense oligonucleotides against vr1
DE10043674A1 (en) * 2000-09-02 2002-03-21 Gruenenthal Gmbh New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
GB0128161D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Receptor protein
CN1984906A (en) 2004-07-15 2007-06-20 日本烟草产业株式会社 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN111455470A (en) * 2020-04-09 2020-07-28 嘉兴菲沙基因信息有限公司 Small fragment DNA library construction method capable of improving data quality of Hi-C library

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4444493B2 (en) * 1997-08-20 2010-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Nucleic acid sequences encoding capsaicin receptors and capsaicin receptor related polypeptides and uses thereof
DE69910538T2 (en) * 1998-01-22 2004-06-24 The Regents Of The University Of California, Oakland NUCLEIC ACID SEQUENCES CODING CAPSAICIN RECEPTORS
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1

Also Published As

Publication number Publication date
AU4237400A (en) 2000-11-02
EP1175504A4 (en) 2002-07-31
JP2003520022A (en) 2003-07-02
CA2370570A1 (en) 2000-10-26
EP1175504A1 (en) 2002-01-30
WO2000063415A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
EP0871703A4 (en) Dna encoding glutamate gated chloride channels
AU2001278797A1 (en) Expression vector using for animal cell
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
DE69635899D1 (en) POLYPEPTIDE THAT SUPPRESSING DIFFERENTIATION
AU4847896A (en) Production of biologically active recombinant bovine follicle stimulating hormone (rec bfsh) in the baculovirus expression system
WO2000063415A8 (en) Dna encoding the human vanilloid receptor vr1
WO2000037487A8 (en) αvβ6 INTEGRIN INHIBITORS
EP1272514A4 (en) Dna encoding human vanilloid receptor vr3
EP0760864A4 (en) Dna encoding glutamate gated chloride channels
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
WO2001094414A3 (en) THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE
HK1047767A1 (en) Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
DE69734596D1 (en) "SMOOTHENED" PROTEINS FROM SWIVELING
MXPA02011938A (en) Dnas encoding mammalian histamine receptor of the h4 subtype.
WO2000071741A3 (en) Dna encoding a human subunit of the 5-ht3 serotonin receptor
WO2003040343A3 (en) Polynucleotide and polypeptide sequences of canine cathepsin s
WO2003040396A3 (en) Polynucleotide and polypeptide sequences of monkey cathepsins
EP0274560A3 (en) Human hematopoietic cell growth potentiating factor
WO2000005405A3 (en) Lafora's disease gene
EP1074619A3 (en) Promoter for neuropeptide FF and use thereof for therapy and diagnostics
EP1219706A3 (en) Production processes for recombinant wolinella succinogenes asparaginase
EP0960935A4 (en) Novel mouse cxc chemokine receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200007421

Country of ref document: ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2370570

Country of ref document: CA

Ref country code: CA

Ref document number: 2370570

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 612492

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000922143

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000922143

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000922143

Country of ref document: EP